Abstract
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.
All Keywords
【초록키워드】 Efficacy, Vaccine, vaccination, therapy, Immunity, anti-Spike IgG, inhibitor, booster, Prospective clinical trial, Patients with cancer, reduced, seroconverted, significant increases in, seronegative patient, were assessed, 【제목키워드】 COVID-19 vaccine, immune response, booster dose, Patients with cancer,
【초록키워드】 Efficacy, Vaccine, vaccination, therapy, Immunity, anti-Spike IgG, inhibitor, booster, Prospective clinical trial, Patients with cancer, reduced, seroconverted, significant increases in, seronegative patient, were assessed, 【제목키워드】 COVID-19 vaccine, immune response, booster dose, Patients with cancer,
{{{ 추상적인 }}}
항-COVID-19 면역 역학은 전향적 임상 시험에서 암 환자에서 평가되었습니다. 면역 저하가 백신 접종 후 4-6개월에 감지되었으며 추가 접종 후 항스파이크 IgG 역가가 유의하게 증가했으며 혈청 음성 환자의 56%가 추가 백신 접종 후 혈청 전환되었습니다. 이전의 항-CD20/BTK 억제제 요법은 백신 효능 감소와 관련이 있었습니다.